AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 159 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $10,466,690 | +53.3% | 242,734 | -20.8% | 0.00% | +100.0% |
Q4 2023 | $6,826,334 | +18.7% | 306,526 | +50.9% | 0.00% | 0.0% |
Q2 2023 | $5,752,613 | -10.8% | 203,129 | -27.7% | 0.00% | 0.0% |
Q1 2023 | $6,449,264 | -35.0% | 280,769 | -20.6% | 0.00% | -50.0% |
Q4 2022 | $9,926,336 | -0.7% | 353,502 | 0.0% | 0.00% | -33.3% |
Q3 2022 | $9,997,037 | -5.2% | 353,502 | -25.7% | 0.00% | 0.0% |
Q2 2022 | $10,547,001 | -26.9% | 475,733 | -4.1% | 0.00% | 0.0% |
Q1 2022 | $14,435,416 | +113.5% | 495,892 | +141.1% | 0.00% | +200.0% |
Q4 2021 | $6,760,000 | -50.4% | 205,646 | -30.4% | 0.00% | -66.7% |
Q3 2021 | $13,640,000 | -36.8% | 295,557 | -24.5% | 0.00% | -40.0% |
Q2 2021 | $21,581,000 | +54.8% | 391,591 | +45.1% | 0.01% | +66.7% |
Q1 2021 | $13,938,000 | -43.6% | 269,902 | -52.6% | 0.00% | -50.0% |
Q4 2020 | $24,691,000 | +26.5% | 569,836 | +2.2% | 0.01% | +20.0% |
Q3 2020 | $19,517,000 | -60.8% | 557,625 | -40.1% | 0.01% | -64.3% |
Q2 2020 | $49,818,000 | +34.5% | 931,521 | -10.8% | 0.01% | +7.7% |
Q1 2020 | $37,036,000 | -25.7% | 1,043,854 | 0.0% | 0.01% | -7.1% |
Q4 2019 | $49,844,000 | +211.5% | 1,043,854 | +111.4% | 0.01% | +180.0% |
Q3 2019 | $16,001,000 | -23.2% | 493,854 | +18.2% | 0.01% | -16.7% |
Q2 2019 | $20,841,000 | -26.0% | 417,825 | 0.0% | 0.01% | -33.3% |
Q1 2019 | $28,178,000 | +46.3% | 417,825 | 0.0% | 0.01% | +28.6% |
Q4 2018 | $19,267,000 | -31.8% | 417,825 | +14.0% | 0.01% | -22.2% |
Q3 2018 | $28,262,000 | -8.4% | 366,476 | 0.0% | 0.01% | -18.2% |
Q2 2018 | $30,868,000 | +3.0% | 366,476 | 0.0% | 0.01% | 0.0% |
Q1 2018 | $29,971,000 | +65.6% | 366,476 | +15.8% | 0.01% | +83.3% |
Q4 2017 | $18,093,000 | -14.4% | 316,476 | 0.0% | 0.01% | -25.0% |
Q3 2017 | $21,125,000 | -33.5% | 316,476 | -48.8% | 0.01% | -38.5% |
Q2 2017 | $31,777,000 | -13.4% | 617,634 | -1.7% | 0.01% | -13.3% |
Q1 2017 | $36,676,000 | +344.8% | 628,027 | +217.8% | 0.02% | +275.0% |
Q4 2016 | $8,246,000 | -26.3% | 197,611 | -10.9% | 0.00% | -20.0% |
Q3 2016 | $11,184,000 | +20.4% | 221,697 | 0.0% | 0.01% | +25.0% |
Q2 2016 | $9,288,000 | +127.1% | 221,697 | +120.1% | 0.00% | +100.0% |
Q1 2016 | $4,090,000 | -59.5% | 100,731 | -35.3% | 0.00% | -60.0% |
Q4 2015 | $10,102,000 | -15.4% | 155,610 | -7.9% | 0.01% | -16.7% |
Q3 2015 | $11,934,000 | -46.9% | 169,049 | -16.4% | 0.01% | -45.5% |
Q2 2015 | $22,482,000 | +83.4% | 202,293 | +55.6% | 0.01% | +83.3% |
Q1 2015 | $12,259,000 | – | 129,994 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |